Announcement on Cabergoline Raw Material Drug Obtaining EU DCP Approval

Hybio Pharmaceutical Co., Ltd.·June 1, 2026·2 pages

✨ AI Summary

Shenzhen Hanyu Pharmaceutical Co., Ltd. has received EU DCP approval for its cabergoline raw material drug, enhancing its competitive position in the global obstetrics and gynecology market. The approval was granted by Ireland's HPRA and involves 24 member countries. This development follows the company's previous approvals in China and Indonesia, paving the way for further international expansion.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Shenzhen Hanyu Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without any false records, misleading statements, or significant omissions.

On May 29, 2026, Shenzhen Hanyu Pharmaceutical Co., Ltd. received the EU DCP approval document issued by the reference member state Ireland (HPRA), confirming that the cabergoline raw material drug produced by the Company has obtained approval through the EU decentralized procedure (DCP). The relevant information is announced as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.